Preoperative Proton Irradiation for High-grade Brain Gliomas.

The goal of this clinical trial is to learn if preopearative proton therapy (PPT) is tolerable in patients with High-grade brain gliomas. It will also learn about the influence on surgical procedure, clinical effects and safety of regular treatment. The main questions it aims to answer are: Does preoprative proton therapy well-tolerated? What maximal dose of PPT is safe? Proposed Treatment Stages 1. Multidisciplinary board (neurosurgeon, radiation therapist, and medical oncologist) decision of patient enrollment. 2. Course of preoperative proton stereotactic radiotherapy (PSRT) directed at the tumor only: GTV=contrast-part of brain giloma, CTV=GTV. Dose regimens: first 3 patients - 4 Gy(RBE) × 5 fractions; subsequent 3 patients - 5 Gy(RBE) × 5 fractions; subsequent 3 patients - 6 Gy(RBE) × 5 fractions. RBE = Relative biological efficacy, equal 1.1 for protons. Should any information regarding unacceptable treatment toxicity emerge, the study will be terminated. 3. Microsurgical resection of the contrast-enhancing portion of the tumor using fluorescence microscopy and, when indicated, neurophysiological monitoring. 4. Contrast-enhanced MRI to assess the resection volume within the first 24-48 hours after surgery. 5. Follow-up evaluation - clinical, morphological, and radiological assessment of the effects of the preoperative and surgical treatment stages, performed 3-4 weeks after the surgical phase. 6. Standard treatment and follow-up: Chemoradiotherapy with a scanned proton beam combined with temozolomide 75 mg/m², given at 2 Gy × 30 fractions, to commence 4-6 weeks after surgery. Adjuvant chemotherapy with temozolomide 150-200 mg/m² on a 5/23 schedule (maintenance chemotherapy), for 12 cycles or until disease progression/unacceptable toxicity. 7. Follow-up - control examinations every 1 month after completion of chemoradiotherapy, then every 3 months for the first year.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* radiologically confirmed (MRI and/or PET with amino-acids) diagnosis of high-grade glioma
* single foci
* ECOG 0-2 status
* tumor location and volume, eligible for gross total resection (GTR)
* signed informed consent

Exclusion Criteria:

* multifocal disease
* ECOG 3-4
* inability to achieve GTR

• BACKGROUNDMcClelland S 3rd, Yeboa DN. The Emerging Paradigm of Preoperative Stereotactic Radiosurgery for Resectable Brain Metastases. JAMA Oncol. 2023 Aug 1;9(8):1073-1074. doi: 10.1001/jamaoncol.2023.1342. No abstract available. PMID 37289443
• BACKGROUNDIvy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15;16(6):1726-36. doi: 10.1158/1078-0432.CCR-09-1961. Epub 2010 Mar 9. PMID 20215542
• BACKGROUNDBisello S, Cilla S, Benini A, Cardano R, Nguyen NP, Deodato F, Macchia G, Buwenge M, Cammelli S, Wondemagegnehu T, Uddin AFMK, Rizzo S, Bazzocchi A, Strigari L, Morganti AG. Dose-Volume Constraints fOr oRganS At risk In Radiotherapy (CORSAIR): An "All-in-One" Multicenter-Multidisciplinary Practical Summary. Curr Oncol. 2022 Sep 27;29(10):7021-7050. doi: 10.3390/curroncol29100552. PMID 36290829
• BACKGROUNDDohopolski M, Schmitt LG, de Vis J, Mostardeiro TR, Anand S, Youssef M, Noch E, Maher E, Sun M, Patel T, Patel A, Barnett S, Lee M, Iakovenko V, Chiu T, Su FC, Pompos A, Lin MH, Cai X, Timmerman R, Dan T, Wardak Z. Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score-Matched Analysis. Adv Radiat Oncol. 2025 May 18;10(8):101813. doi: 10.1016/j.adro.2025.101813. eCollection 2025 Aug. PMID 40611877
• BACKGROUNDGulidov I, Gordon K, Semenov A, Gogolin D, Lepilina O, Golovanova O, Dujenko S, Medvedeva K, Koryakin S, Ivanov S, Kaprin A. Proton re-irradiation of unresectable recurrent brain gliomas: clinical outcomes and toxicity. J BUON. 2021 May-Jun;26(3):970-976. PMID 34268961
• BACKGROUNDMatsuda M, Mizumoto M, Kohzuki H, Sugii N, Sakurai H, Ishikawa E. High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis. Radiat Oncol. 2023 Feb 23;18(1):38. doi: 10.1186/s13014-023-02236-1.